Haben selektive COX-2-Hemmer unerwünschte renale und kardiovaskuläre Wirkungen [Do selective COX-2 inhibitors have adverse renal and cardiovascular effects?].


Autoria(s): Mathieu C.; Meier P.; Meyer zu Starten A.; Burnier M.
Data(s)

2005

Resumo

Selective cyclooxygenase-2-inhibitors (COX-2) were developed as an alternative to the non-steroidal anti-inflammatory drugs (NSAID) in order to reduce their known gastrointestinal and renal toxicity. Several recent studies have shown the complex mechanism of the cyclooxygenase-2. The inhibition of the COX-2 has effects on renal hemodynamics, renal salt and water retention and may increase the thromboembolic and therefore the cardiovascular risk. The renal toxicity of the COX-2 inhibitors is similar to that of traditional NSAID. Regarding these data, COX-2 inhibitors should be prescribed with much caution to high risk patients, that is, patients with renal failure and/or cardiovascular diseases.

Identificador

http://serval.unil.ch/?id=serval:BIB_5BF09D2EFD14

isbn:1661-8157 (Print)

pmid:16335308

Idioma(s)

de

Fonte

Praxis, vol. 94, no. 47, pp. 1851-1858

Palavras-Chave #Anti-Inflammatory Agents, Non-Steroidal/administration & dosage; Anti-Inflammatory Agents, Non-Steroidal/toxicity; Cardiovascular Diseases/chemically induced; Cardiovascular Diseases/mortality; Cyclooxygenase 2 Inhibitors/administration & dosage; Cyclooxygenase 2 Inhibitors/toxicity; Dose-Response Relationship, Drug; Humans; Kidney Diseases/chemically induced; Kidney Diseases/mortality; Naproxen/administration & dosage; Naproxen/toxicity; Pyrazoles/administration & dosage; Pyrazoles/toxicity; Risk Assessment; Sulfonamides/administration & dosage; Sulfonamides/toxicity; Thromboembolism/chemically induced; Thromboembolism/mortality
Tipo

info:eu-repo/semantics/review

article